The fastest-growing line item in American fashion retail right now isn't a product. It's the return.

As a wave of consumers loses weight on GLP-1 medications like Ozempic, Wegovy and Zepbound, the clothes they bought six months ago no longer fit — and they are sending them back in record numbers. The Wall Street Journal reports that Americans on GLP-1s are overwhelming retailers with nonstop returns, with one online suit seller watching returns jump 50% in a single year. At peak weight loss, a patient can shed a full clothing size every month — which means a single shopper can cycle through three or four wardrobes in a year.

The data backs up the anecdotes. The share of apparel exchanges in which shoppers sized down has now climbed for three straight years, hitting 14.6% in 2025, according to industry figures cited by Retail Dive. With roughly 23% of U.S. households now using GLP-1 medications, 80% of users say they anticipate needing new clothes as their bodies change, and more than half have already bought replacements.

Returns are margin poison

For retailers, the problem isn't the new demand — it's the churn. Returns are one of the most expensive things in retail: they cost labor to process, frequently can't be resold at full price, and scramble inventory planning. For a $1 billion retailer that already sees about 20% of purchases come back, a 5-to-10-percentage-point bump in returns can carve roughly $20 million out of gross margin. Analysts warn U.S. retailers could absorb up to a $5 billion margin hit by 2027 from misaligned inventory and rising returns alone.

The deeper challenge is forecasting. Merchants buy their size curves six to twelve months out. A customer base that is physically shrinking on a monthly basis breaks that model: the size 16s pile up in clearance while the size 8s sell out, and the imbalance shifts again next quarter. Grocers are retooling private-label and wellness assortments for the same shoppers; apparel sellers have to retool something much harder to change quickly — their buy.

Who wins, who loses

This isn't all bad news for retail. The same shift is projected to unlock up to $13 billion in incremental annual apparel spending as millions of people rebuild their closets. The clearest beneficiaries are the formats built for churn: off-price chains like T.J. Maxx, discounters like Walmart and Target, and subscription and rental players like Stitch Fix and Rent the Runway, where a constantly changing body is a feature, not a bug.

The losers are concentrated at the top of the size range. Plus-size specialist Torrid posted a 14.3% sales decline in the fourth quarter of fiscal 2025, swung to a net loss, and is closing 30 stores in the first half of 2026 — a brand caught directly in the path of a demographic sizing down.

For retail's solution providers, the GLP-1 returns wave is a flashing signal about where to invest: AI-driven size and fit recommendations that predict a shopper's next size, returns-management and reverse-logistics tooling, and resale infrastructure to recapture value from all those barely-worn garments. The medication may be the disruptor, but the retailers that treat sizing as a live data problem — rather than a static curve set a year in advance — will be the ones that keep the margin instead of mailing it back.

This article is an aggregation and analysis of reporting from The Wall Street Journal, Retail Dive, CNBC, TheStreet and others.

GLP-1 medications affect health, weight and body image, which can be sensitive topics. This piece covers the retail-industry impact only and is not medical advice.